News | Astellas Pharma Inc.
Find out the latest news and updates from Astellas Pharma Inc., a global biopharmaceutical company. Learn about its products, pipeline, collaborations, approvals, and events in various therapeutic areas.
Newsroom | Astellas Pharma Inc.
Oct 2, 2024 · You can see the latest news, stories, and other materials related to our initiatives.
News | Astellas Pharma Inc.
Jan 29, 2024 · Latest and past news available. – Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival –– If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in ...
News | Astellas Pharma Inc.
Oct 12, 2021 · Latest and past news available. TOKYO and BOTHELL, Wash. – October 12, 2021 – Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869).
News | Astellas Pharma Inc.
Mar 26, 2024 · VYLOY™ is an anti-CLDN18.2 monoclonal antibody approved by MHLW in Japan for CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. It is used in combination with chemotherapy and has shown improved progression-free survival and overall survival in Phase 3 trials.
News | Astellas Pharma Inc.
Dec 18, 2023 · News from Astellas. Latest and past news available. – PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial –– Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy –
News | Astellas Pharma Inc.
Jan 9, 2023 · News from Astellas. Latest and past news available. Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies’ product, for the treatment of Pompe Disease Selecta to receive a $10M upfront payment and eligible to receive up to $340M for certain additional development and ...
News | Astellas Pharma Inc.
Aug 5, 2023 · IZERVAY is a complement C5 inhibitor that reduces the rate of GA progression in patients with AMD. It is the only approved GA treatment with a statistically significant effect across two Phase 3 trials and may preserve vision.
News | Astellas Pharma Inc.
Apr 22, 2024 · Astellas plans to file objections to the Report. In July 2023, Astellas filed this lawsuit in the U.S. District Court for the District of Delaware asserting that Zydus’ and Lupin’s generic versions of Myrbetriq TM infringe the ‘451 patent.
News | Astellas Pharma Inc.
Sep 24, 2024 · News from Astellas. Latest and past news available. - Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing chemotherapy, the current standard of care for first-line treatment of radically unresectable ...